Compliance & Validation — Documented
ISO 27001, SOC 2 Type II
Insilico Medicine
End-to-end AI drug discovery platform covering target identification through clinical candidate nomination.
Insilico Medicine uses generative AI and deep learning across the drug discovery pipeline. Their PandaOmics platform identifies disease targets while Chemistry42 generates novel molecules. They became one of the first companies to advance an AI-discovered and AI-designed drug into Phase II clinical trials, targeting idiopathic pulmonary fibrosis. Insilico Medicine listed on the Hong Kong Stock Exchange in December 2025, following a $110 million Series E round earlier that year.
- Headquarters
- Hong Kong, China
- Founded
- 2014
- Compliance
- ISO 27001, SOC 2 Type II
- Deployment options
- cloud, private-cloud
- Website
- https://insilico.com
- https://www.linkedin.com/company/in-silico-medicine-inc
Categories
AI Use Cases
- ADMET & Toxicity Prediction
- Hit Identification & Lead Optimization
- Target Identification & Validation
Vendor Scorecard
100% — Complete coverage. Coverage score — how completely Atlas documents Insilico Medicine across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
Deployment & Hosting — Documented
cloud, private cloud
Pricing Transparency — Documented
Annual license + usage
Implementation & Onboarding — Documented
3–6 months
Organization & Role Fit — Documented
Biotech Startup, Mid-Size Biotech, Large Pharma, Drug Discovery, R&D Leadership
Solution Scope — Documented
ADMET Prediction, Molecular Generation, Natural Language Processing, Target Identification
Company Viability — Documented
Public, 500+ employees, Founded 2014
Always ask the vendor
Not captured in Atlas data — confirm directly. Excluded from the score above.
Data Rights & IP
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Model Credibility & Explainability
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?
Clinical Trial Activity
11 registered trials where Insilico Medicine is the lead sponsor (6 currently recruiting). Source: ClinicalTrials.gov, verified 2026-07-29.
Phases: Phase 1 (6), Phase 2 (3), Phase 3 (1), Phase 1/Phase 2 (1)
Top conditions studied: Advanced Solid Tumor, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF), Advanced and/or Metastatic Solid Tumors, Advanced Solid Tumors
- Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors (NCT06724042, not yet recruiting)
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) (NCT07687459, not yet recruiting)
- A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM8969 (NCT07581431, recruiting)
- Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) (NCT07265570, recruiting)
- Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors (NCT06414460, recruiting)
Evidence & Outcomes
Sanofi collaboration worth up to $1.2 billion in milestones
Sanofi entered a research collaboration using Insilico's Pharma.AI platform to advance drug candidates across multiple targets, with Insilico eligible for up to $1.2 billion in potential milestone payments plus royalties.
press release (Insilico Medicine (GlobeNewswire)) · 2022-11-08 — Partner: Sanofi
U.S. FDA Orphan Drug Designation for its generative-AI-discovered IPF drug (INS018_055)
The U.S. FDA granted Orphan Drug Designation to INS018_055 (rentosertib), Insilico's candidate for idiopathic pulmonary fibrosis whose biological target was AI-identified and whose molecule was AI-generated, recognizing its development for a rare disease.
press release (Insilico Medicine (GlobeNewswire)) · 2023-02-08
Generative-AI–discovered IPF drug (rentosertib) reports topline Phase IIa results
Insilico advanced rentosertib (INS018_055), a drug with both an AI-discovered target and an AI-generated molecule, through a Phase IIa trial in idiopathic pulmonary fibrosis. Results were published in Nature Medicine — among the first peer-reviewed clinical readouts for a fully generative-AI–originated drug.
press release (Insilico Medicine (PR Newswire)) · 2025-06-03
Questions to Ask This Vendor
- Which therapeutic areas have the most Chemistry42 training data?
- How is the PandaOmics target confidence score validated?
- What wet-lab validation partnerships do you offer?
- How do you handle IP ownership of generated molecules?